Suppr超能文献

COVID-19疫苗接种后出现双侧腋窝淋巴结病并进行淋巴结手术活检:一例报告

Bilateral Axillary Lymphadenopathy After COVID-19 Vaccine Presenting for Lymph Node Surgical Biopsy: A Case Report.

作者信息

Taylor Amanda, Michael John, Sciarra John, Kuchciak Andrzej, Masri Mohammed M

机构信息

Anesthesiology, Larkin Community Hospital, South Miami, USA.

School of Medicine, Lake Erie College of Osteopathic Medicine (LECOM), Tampa, USA.

出版信息

Cureus. 2023 Mar 6;15(3):e35834. doi: 10.7759/cureus.35834. eCollection 2023 Mar.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic ravaged China, made its way to Thailand and Japan, and ultimately spread across the globe. Despite all efforts to contain the virus, hundreds of millions of positive cases and millions of deaths have been reported worldwide. Due to the vastness and severity of this virus, there was a desperate need for a vaccine, quickly. The COVID-19 vaccination was created urgently under emergency use authorization (EUA) by the US Food and Drug Administration (FDA) in less than one year, a process typically taking over 10 years. With this expedited creation time, there is also a shortened time frame for clinical trials, which is commonly used to evaluate for effectiveness and identify any potential side effects or adverse reactions to the created vaccine. We will discuss some potential side effects of receiving the Pfizer-BioNTech COVID-19 mRNA vaccination. In this case report, we discuss one individual who received two doses of the Pfizer-BioNTech COVID-19 mRNA vaccine and experienced a previous unreported adverse side effect of non-self-remitting bilateral axillary lymphadenopathy. This reaction was not originally seen during the clinical trial phase of the vaccine creation, which caused this individual to obtain a full medical workup including ultrasound, computed tomography (CT) scans, and blood work and ultimately needing surgical intervention to have the axillary lymphadenopathy excised. We aim to shed light on a new, undocumented adverse reaction that should be included in physicians' differential diagnoses in individuals after receiving the COVID-19 vaccine, particularly the Pfizer-BioNTech COVID-19 mRNA vaccination. This information could help future patients avoid unnecessary extensive medical workups, surgical procedures, being exposed to anesthesia, or having the burden of additional unwarranted healthcare costs.

摘要

2019年冠状病毒病(COVID-19)大流行肆虐中国,蔓延至泰国和日本,最终在全球传播。尽管采取了一切措施来控制病毒,但全球仍报告了数亿例阳性病例和数百万例死亡。由于这种病毒的传播范围广、危害大,人们迫切需要一种疫苗。美国食品药品监督管理局(FDA)在不到一年的时间里,根据紧急使用授权(EUA)紧急批准了COVID-19疫苗,而这一过程通常需要10年以上。由于疫苗研发时间的加快,临床试验的时间框架也缩短了,而临床试验通常用于评估疫苗的有效性,并确定所研发疫苗的任何潜在副作用或不良反应。我们将讨论接种辉瑞-生物科技公司COVID-19 mRNA疫苗可能出现的一些副作用。在本病例报告中,我们讨论了一名接种了两剂辉瑞-生物科技公司COVID-19 mRNA疫苗的个体,该个体出现了一种此前未报告的非自行缓解的双侧腋窝淋巴结病的不良副作用。这种反应在疫苗研发的临床试验阶段并未出现,这使得该个体接受了包括超声、计算机断层扫描(CT)和血液检查在内的全面医学检查,最终需要进行手术干预以切除腋窝淋巴结病。我们旨在揭示一种新的、未记录的不良反应,医生在为接种COVID-19疫苗后的个体进行鉴别诊断时应将其考虑在内,尤其是接种辉瑞-生物科技公司COVID-19 mRNA疫苗的个体。这些信息可以帮助未来的患者避免不必要的广泛医学检查、外科手术、接触麻醉或承担额外的不必要医疗费用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f4d/10075141/6ec3ab5fdf70/cureus-0015-00000035834-i01.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验